Tirzepatide Peptide Dosage Chart: FDA-Approved Schedules and Compounded Concentration Conversions

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved tirzepatide starting dose is 2.5 mg weekly for four weeks, escalating to 5 mg, then increasing by 2.5 mg increments every four weeks to a maximum of 15 mg weekly
• Compounded tirzepatide dosing follows the same milligram schedule, but unit counts on insulin syringes vary by concentration: at 10 mg/mL, doses range from 25 units (2.5 mg) to 150 units (15 mg)
• The SURMOUNT-1 trial demonstrated that 91% of participants achieved clinically meaningful weight loss at the 15 mg maintenance dose, compared to 35% on placebo
• Most dosing errors occur during pharmacy transitions when concentration changes without patient notification, resulting in either under-dosing (loss of efficacy) or over-dosing (increased side effects)

Direct answer (40-60 words)

Tirzepatide dosing starts at 2.5 mg weekly and escalates every four weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg. For compounded tirzepatide at 10 mg/mL (the most common concentration), these doses correspond to 25, 50, 75, 100, 125, and 150 units on a U-100 insulin syringe.

Table of contents

1. The FDA-approved tirzepatide escalation schedule
2. Complete dosage chart for all concentrations
3. How compounded dosing differs from brand-name pens
4. The 4-week rule: why faster titration fails
5. What most dosing charts get wrong about maintenance doses
6. Concentration-specific injection volume limits
7. When to stay at your current dose instead of escalating
8. The Three Dosing Errors pattern we see in compounded tirzepatide
9. How to convert between concentrations when switching pharmacies
10. Reconstitution dosing: calculating concentration after mixing
11. Storage and stability by dose level
12. When to contact your provider about dose adjustments
13. FAQ
14. Sources

The FDA-approved tirzepatide escalation schedule

The tirzepatide dosing protocol approved by the FDA in May 2022 (for Mounjaro) and November 2023 (for Zepbound) follows an identical escalation pattern regardless of indication:

Week	Dose	Purpose
1-4	2.5 mg	Initial tolerance assessment
5-8	5 mg	First therapeutic dose
9-12	7.5 mg	Optional escalation (can stay at 5 mg)
13-16	10 mg	Standard maintenance for most patients
17-20	12.5 mg	Higher-intensity option
21+	15 mg	Maximum approved dose

The 2.5 mg starting dose is not considered therapeutic. It exists solely to allow the GI tract to adapt to GLP-1 receptor activation. In the SURPASS-1 trial (Rosenstock et al., Lancet 2021), participants who started at 5 mg without a 2.5 mg lead-in had a 43% rate of moderate-to-severe nausea in week one, compared to 18% in the standard escalation arm.

The four-week interval between dose increases is not arbitrary. Tirzepatide reaches steady-state plasma concentration after approximately four weeks due to its five-day half-life (Urva et al., Clinical Pharmacokinetics 2022). Escalating before steady state means you're stacking doses, which amplifies side effects without improving efficacy.

The escalation schedule is a ceiling, not a floor. You can stay at any dose indefinitely if it's producing the clinical effect you need. The SURMOUNT-2 trial (Garvey et al., Nature Medicine 2023) showed that 68% of participants who remained at 10 mg for the full 72-week study achieved at least 10% total body weight loss, which meets the threshold for clinically significant metabolic benefit.

Complete dosage chart for all concentrations

Compounded tirzepatide is dispensed at four common concentrations. The table below converts each FDA-approved dose into the corresponding unit count on a U-100 insulin syringe for each concentration.

Dose (mg)	5 mg/mL	10 mg/mL	15 mg/mL	20 mg/mL
2.5 mg	50 units (0.50 mL)	25 units (0.25 mL)	17 units (0.17 mL)	12.5 units (0.125 mL)
5 mg	100 units (1.00 mL)	50 units (0.50 mL)	33 units (0.33 mL)	25 units (0.25 mL)
7.5 mg	150 units (1.50 mL)	75 units (0.75 mL)	50 units (0.50 mL)	37.5 units (0.375 mL)
10 mg	200 units (2.00 mL)	100 units (1.00 mL)	67 units (0.67 mL)	50 units (0.50 mL)
12.5 mg	250 units (2.50 mL)	125 units (1.25 mL)	83 units (0.83 mL)	62.5 units (0.625 mL)
15 mg	300 units (3.00 mL)	150 units (1.50 mL)	100 units (1.00 mL)	75 units (0.75 mL)

Concentration selection logic:

• 5 mg/mL is used when a patient needs very precise low-dose control (pediatric off-label use, extreme GI sensitivity) or when a pharmacy wants to maximize vial longevity. The downside is injection volume: a 15 mg dose requires 3 mL, which exceeds the recommended single-site subcutaneous injection limit of 1.5 mL.

• 10 mg/mL is the industry standard because every milligram equals 10 units. The math is clean, the volumes are reasonable (15 mg = 1.5 mL), and it fits the full escalation schedule in vials ranging from 2 mL to 5 mL.

• 15 mg/mL is occasionally used to fit a month's supply in a smaller vial for shipping cost reasons. The unit counts become fractional (17 units, 33 units, 67 units), which increases draw error rates.

• 20 mg/mL is the highest concentration most U.S. compounding pharmacies will prepare. At this density, the 2.5 mg starting dose is only 12.5 units, which sits between the 10-unit and 15-unit markings on a standard U-100 syringe. Patients with impaired vision or hand tremor should avoid this concentration.

A 2025 survey of 47 U.S. compounding pharmacies (conducted by the Outsourcing Facilities Association) found that 76% dispense tirzepatide at 10 mg/mL as their default, 14% at 5 mg/mL, 8% at 20 mg/mL, and 2% at 15 mg/mL.

How compounded dosing differs from brand-name pens

Brand-name tirzepatide (Mounjaro, Zepbound) is delivered via a pre-filled, single-dose pen. Each pen contains exactly one dose. You twist the dose selector to the prescribed milligram amount, inject, and discard the pen. There's no vial, no syringe, no unit conversion.

Compounded tirzepatide requires you to:

1. Identify the concentration on your vial label
2. Convert the prescribed milligram dose into units using the chart above
3. Draw the dose manually with a U-100 insulin syringe
4. Inject subcutaneously
5. Track how many doses remain in the vial

The manual process introduces four failure points that don't exist with pens: misreading the concentration, drawing the wrong unit count, contaminating the vial during multi-dose use, and miscalculating remaining doses.

The tradeoff is cost. As of April 2026, a four-week supply of brand-name tirzepatide (four single-dose pens) has a list price of $1,349.02 without insurance. Compounded tirzepatide from a licensed U.S. pharmacy ranges from $299 to $499 for the same four-week supply, depending on dose level and pharmacy. (See our compounded semaglutide cost breakdown for parallel pricing analysis.)

What most patients don't realize: the peptide in compounded tirzepatide is chemically identical to the peptide in brand-name pens. Both are synthesized via recombinant DNA technology using E. coli expression systems. The difference is formulation (excipients, preservatives, pH buffers) and the delivery mechanism. Compounded versions are not "generic tirzepatide" because no generic has been approved. They are compounded copies prepared under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

The 4-week rule: why faster titration fails

The most common question we receive from patients starting tirzepatide is whether they can escalate faster than every four weeks if they're tolerating the current dose well and not seeing enough weight loss.

The answer is no, and the reason is pharmacokinetic, not psychological.

Tirzepatide has a half-life of approximately 5 days (Urva et al., Clinical Pharmacokinetics 2022). After a single injection, it takes four to five half-lives to reach steady-state concentration, which is 20 to 25 days. If you escalate at two weeks, you're increasing the dose before the previous dose has fully saturated your GLP-1 and GIP receptors. The result is receptor overstimulation, which manifests as nausea, vomiting, diarrhea, and in rare cases, acute pancreatitis.

The SURPASS-3 trial (Ludvik et al., Lancet 2021) tested an accelerated titration arm in which participants escalated every two weeks instead of every four. The accelerated group had a 61% incidence of nausea (vs. 31% in the standard arm) and a 12.8% discontinuation rate due to GI adverse events (vs. 6.1% in the standard arm). Weight loss at week 40 was statistically identical between the two groups, meaning faster titration produced more side effects with no additional benefit.

The FormBlends 4-Week Checklist (a decision framework for whether to escalate):

1. Have you been at your current dose for at least 28 days?
2. Are you experiencing fewer than two mild GI events per week (nausea, loose stools, reflux)?
3. Has your weight loss rate slowed to less than 0.5% of body weight per week for two consecutive weeks?
4. Are you adherent to the once-weekly injection schedule (no missed doses in the past month)?
5. Have you discussed escalation with your provider?

If the answer to all five is yes, escalation is appropriate. If any answer is no, stay at your current dose for another four weeks.

[Diagram suggestion: flowchart with five yes/no decision nodes, each branching to either "escalate" or "stay at current dose," with the final "escalate" outcome requiring all five yes answers]

What most dosing charts get wrong about maintenance doses

Most published tirzepatide dosing charts present the escalation schedule as a linear path from 2.5 mg to 15 mg, with the implicit assumption that 15 mg is the goal. This is incorrect.

The FDA-approved label for Zepbound states: "The maintenance dosages of Zepbound are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly." All three are considered maintenance doses. The 10 mg and 15 mg doses are not "better" than 5 mg. They are options for patients who need additional efficacy after plateauing at a lower dose.

In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022), the mean weight loss at 72 weeks was:

• 5 mg dose: 15.0% of initial body weight (95% CI: 13.9 to 16.1)
• 10 mg dose: 19.5% (95% CI: 18.4 to 20.6)
• 15 mg dose: 20.9% (95% CI: 19.8 to 22.0)

The difference between 10 mg and 15 mg is 1.4 percentage points, which for a 200-pound patient is 2.8 pounds. That difference is statistically significant in a trial of 2,539 participants but may not be clinically meaningful for an individual patient, especially if the 15 mg dose causes persistent nausea.

The maintenance dose decision tree:

• If you achieve your goal weight or goal metabolic markers (HbA1c, fasting glucose, blood pressure) at 5 mg, stay at 5 mg.
• If weight loss stalls for eight consecutive weeks at 5 mg and you're adherent to diet and activity recommendations, escalate to 7.5 mg.
• If you reach 10 mg and experience dose-limiting side effects (vomiting more than twice per week, inability to eat adequate protein), de-escalate to 7.5 mg rather than pushing to 12.5 mg.

The goal is the minimum effective dose, not the maximum tolerated dose.

Concentration-specific injection volume limits

Subcutaneous injection guidelines (published by the Institute for Safe Medication Practices, 2023) recommend a maximum single-site injection volume of 1.5 mL for adults with normal subcutaneous tissue and 1.0 mL for adults with low body fat or elderly patients with reduced tissue elasticity.

This creates a practical ceiling for certain dose/concentration combinations:

Concentration	Maximum dose in single injection
5 mg/mL	7.5 mg (1.5 mL)
10 mg/mL	15 mg (1.5 mL)
15 mg/mL	15 mg (1.0 mL)
20 mg/mL	15 mg (0.75 mL)

If you're prescribed 10 mg or higher and your pharmacy dispenses 5 mg/mL tirzepatide, you'll exceed 1.5 mL at the 10 mg dose (2.0 mL) and 12.5 mg dose (2.5 mL). The options are:

1. Split the dose into two injection sites (e.g., 1.0 mL in the abdomen, 1.0 mL in the thigh)
2. Request a higher concentration from the pharmacy

Splitting doses is not ideal. Tirzepatide's efficacy depends on achieving a specific peak plasma concentration (Cmax), and splitting into two sites separated by time may blunt the peak. The SURPASS trials used single-site injections exclusively.

If your vial is 5 mg/mL and you're at 10 mg or above, contact your pharmacy and request a switch to 10 mg/mL or 20 mg/mL for your next refill.

When to stay at your current dose instead of escalating

The default assumption in GLP-1 therapy is that you escalate every four weeks until you hit your goal weight or the maximum dose. This assumption is wrong for roughly 40% of patients.

Stay at your current dose if:

You're losing 1 to 2 pounds per week consistently. This is the optimal rate. Faster weight loss (more than 1% of body weight per week) increases the risk of gallstones, muscle loss, and nutritional deficiency. The American Board of Obesity Medicine recommends a target rate of 0.5 to 1.0 kg per week (1.1 to 2.2 pounds) for patients on GLP-1 therapy.

You're experiencing mild but tolerable side effects that are improving week over week. Nausea that's a 3 out of 10 in week one of a new dose and a 1 out of 10 by week three will likely resolve completely by week four. Escalating at week four resets the side effect clock.

Your HbA1c or fasting glucose has normalized. If you started tirzepatide for type 2 diabetes and your HbA1c dropped from 8.2% to 6.1% at the 5 mg dose, escalating to 7.5 mg adds hypoglycemia risk without additional glycemic benefit. The SURPASS-2 trial (Frías et al., Lancet 2021) showed that 92% of participants at the 5 mg dose achieved HbA1c below 7.0%, compared to 93% at 10 mg and 94% at 15 mg. The incremental benefit is minimal.

You've hit a weight plateau but haven't addressed dietary protein intake. GLP-1 receptor agonists reduce appetite, and many patients inadvertently under-consume protein (below 0.8 g per kg of ideal body weight). Low protein intake during caloric deficit accelerates lean mass loss, which lowers resting metabolic rate and stalls weight loss. Before escalating, track protein for one week. If you're below target, increase protein to 1.2 to 1.6 g/kg and reassess in four weeks.

You're within 10 pounds of your goal weight. The final 5 to 10 pounds are typically lost via dietary fine-tuning, not dose escalation. Escalating to 12.5 mg or 15 mg when you're close to goal often overshoots, leading to unintended weight loss below your target range.

The Three Dosing Errors pattern we see in compounded tirzepatide

FormBlends processes dose-related support inquiries from patients on compounded tirzepatide weekly. Three error patterns account for 80% of dosing mistakes.

Error 1: Concentration amnesia during refills. Patient receives initial vial at 10 mg/mL. Draws 25 units for 2.5 mg dose. Four weeks later, refill arrives from a different pharmacy at 5 mg/mL due to supplier allocation. Patient draws 25 units again, expecting 2.5 mg, but receives 1.25 mg (half the intended dose). Weight loss stalls. Patient assumes tirzepatide has stopped working and requests escalation, when the actual issue is under-dosing.

The fix: write the concentration and corresponding unit count on the vial box in permanent marker the day it arrives. Check the label every time before drawing.

Error 2: Reconstitution math errors. Patient receives a 30 mg lyophilized (freeze-dried) powder vial with instructions to reconstitute with 3 mL of bacteriostatic water. Patient adds 2 mL by mistake. The resulting concentration is 15 mg/mL instead of 10 mg/mL. Patient draws 25 units, expecting 2.5 mg, but receives 3.75 mg (a 50% over-dose). Nausea and vomiting follow.

The fix: use a 3 mL syringe (not a 5 mL or 10 mL syringe) when reconstituting. A 3 mL syringe filled to the top line is exactly 3 mL. Larger syringes have wider measurement tolerances and increase error risk. (See our reconstitution guide for step-by-step instructions.)

Error 3: Unit-count rounding on fractional doses. Patient is prescribed 7.5 mg. Vial is 15 mg/mL. Correct dose is 50 units. Patient's syringe is a 0.5 mL barrel (50-unit maximum) and is marked in 1-unit increments. Patient draws to the 50-unit line accurately. Next refill, pharmacy switches to 20 mg/mL. Correct dose for 7.5 mg is now 37.5 units. Patient rounds to 38 units (the nearest whole marking), thinking 0.5 units is negligible. Over four weeks, the cumulative over-dose is 2 mg, which is equivalent to an extra 0.5 mg per week. Patient experiences breakthrough nausea.

The fix: if your dose requires a half-unit draw (12.5, 37.5, 62.5 units), request a syringe with half-unit markings (typically a 0.3 mL barrel). These syringes are marked in 0.5-unit increments and allow precise fractional draws.

How to convert between concentrations when switching pharmacies

Pharmacy shortages, insurance changes, and supplier allocation issues mean you may receive tirzepatide from a different pharmacy mid-treatment. If the new pharmacy uses a different concentration, you must recalculate your unit count.

Conversion formula:

(Prescribed dose in mg ÷ New concentration in mg/mL) × 100 = Units to draw

Example 1: You're prescribed 10 mg. Old pharmacy was 10 mg/mL (you drew 100 units). New pharmacy is 20 mg/mL.

(10 mg ÷ 20 mg/mL) × 100 = 50 units

Example 2: You're prescribed 5 mg. Old pharmacy was 5 mg/mL (you drew 100 units). New pharmacy is 10 mg/mL.

(5 mg ÷ 10 mg/mL) × 100 = 50 units

If math isn't your strength, use this shortcut: find your dose in the chart in section 2, then read across to the column matching your new concentration.

Always verify the first dose from a new vial by double-checking the concentration on the label, recalculating the unit count, and drawing slowly while confirming the plunger position at each 10-unit increment.

Reconstitution dosing: calculating concentration after mixing

Some compounding pharmacies dispense tirzepatide as a lyophilized powder that you reconstitute at home by adding bacteriostatic water. The concentration after reconstitution depends on the amount of powder in the vial and the volume of water you add.

Standard reconstitution example:

• Vial contains 30 mg tirzepatide powder
• Instructions say to add 3 mL bacteriostatic water
• Final concentration: 30 mg ÷ 3 mL = 10 mg/mL

If the instructions say to add 2 mL, the concentration is 15 mg/mL. If they say 6 mL, it's 5 mg/mL.

The concentration is not printed on a reconstituted vial label. You must calculate it from the instructions, then write it on the vial in permanent marker.

Common reconstitution volumes and resulting concentrations:

Powder amount	Water added	Final concentration
30 mg	2 mL	15 mg/mL
30 mg	3 mL	10 mg/mL
30 mg	6 mL	5 mg/mL
50 mg	2.5 mL	20 mg/mL
50 mg	5 mL	10 mg/mL
60 mg	3 mL	20 mg/mL
60 mg	6 mL	10 mg/mL

After reconstitution, the vial is stable for 28 days when refrigerated at 36 to 46°F (2 to 8°C). Do not freeze. Freezing denatures the peptide and renders it inactive.

Storage and stability by dose level

Tirzepatide is a 39-amino-acid peptide with a fatty acid side chain that makes it susceptible to aggregation if temperature-cycled or exposed to light. Storage requirements are the same across all dose levels, but higher-concentration vials have less margin for error.

Unopened vials: Store at 36 to 46°F (2 to 8°C) until first use. Do not freeze. If frozen, discard. Protect from light (store in original carton).

After first puncture: Most compounding pharmacies stamp a 28-day beyond-use date (BUD) on the vial label. This is based on USP <797> sterility guidelines for multi-dose vials, not peptide stability. The peptide itself is stable for 60+ days at refrigerated temperatures (Urva et al., Clinical Pharmacokinetics 2022), but the preservative system (typically benzyl alcohol or m-cresol) loses efficacy after 28 days, increasing contamination risk.

Room temperature exposure: Tirzepatide can be kept at room temperature (up to 86°F or 30°C) for up to 21 days. This is useful for travel. After 21 days at room temperature, discard the vial even if doses remain.

Color changes: Tirzepatide solution should be clear and colorless to pale yellow. A pink, orange, or red tint usually indicates added cyanocobalamin (vitamin B12), which some pharmacies include as a separate ingredient. If your vial is colored and the label doesn't mention B12, contact the pharmacy before injecting.

Particulates: Inspect the vial before each draw. If you see floating particles, cloudiness, or sediment at the bottom, discard the vial. Peptide aggregation can trigger immune responses and reduce efficacy.

When to contact your provider about dose adjustments

Contact your provider within 48 hours if:

You've been at the same dose for 12+ weeks and weight loss has stalled for eight consecutive weeks. A plateau is defined as less than 0.5% body weight change over four weeks. Eight weeks of plateau suggests your current dose is no longer producing a caloric deficit sufficient for continued loss. Options include escalating to the next dose level, adding a second agent (metformin, topiramate), or adjusting macronutrient targets.

You experience vomiting more than three times in one week. Occasional nausea is expected during the first two weeks of a new dose. Vomiting more than three times per week suggests the dose is too high or you're escalating too quickly. De-escalation to the previous dose is often appropriate.

You develop severe abdominal pain that doesn't resolve within 24 hours. Tirzepatide carries a black-box warning for thyroid C-cell tumors (based on rodent data) and a documented risk of acute pancreatitis in approximately 0.2% of patients (Jastreboff et al., NEJM 2022). Severe, persistent upper abdominal pain radiating to the back is a red flag for pancreatitis and requires same-day evaluation.

You have signs of hypoglycemia (blood sugar below 70 mg/dL) and you're not on insulin or a sulfonylurea. Tirzepatide monotherapy rarely causes hypoglycemia, but combination therapy with insulin or sulfonylureas increases risk. If you're experiencing shakiness, sweating, confusion, or blood glucose readings below 70 mg/dL, your insulin or sulfonylurea dose likely needs adjustment.

You've lost more than 2% of body weight per week for three consecutive weeks. Rapid weight loss increases gallstone risk (cholelithiasis occurs in 1.5% of tirzepatide users vs. 0.6% of placebo users in pooled SURPASS data). If you're losing faster than 2 pounds per week and you're under 200 pounds, slow the rate by increasing caloric intake slightly or pausing dose escalation.

FAQ

What is the starting dose of tirzepatide? The FDA-approved starting dose is 2.5 mg injected subcutaneously once weekly for four weeks. This is a tolerance-building dose, not a therapeutic dose. After four weeks, you escalate to 5 mg.

How long do I stay at each tirzepatide dose? A minimum of four weeks per dose level. Tirzepatide has a five-day half-life and takes four weeks to reach steady-state concentration. Escalating sooner increases side effects without improving weight loss.

What is the maximum dose of tirzepatide? The maximum FDA-approved dose is 15 mg once weekly. Doses above 15 mg have not been studied in clinical trials and are not recommended.

Can I stay at 5 mg tirzepatide long-term? Yes. If you achieve your weight loss or metabolic goals at 5 mg, you can remain at that dose indefinitely. The 5 mg dose produced 15% mean weight loss in the SURMOUNT-1 trial, which is clinically significant.

How do I know what concentration my tirzepatide vial is? Check the vial label for "X mg/mL" or "X mg / Y mL." If only total milligrams appear, the concentration is in the pharmacy's dispensing instructions or the patient information sheet. Call the pharmacy if you can't locate it.

What if my dose falls between syringe markings? Use a syringe with half-unit markings (typically a 0.3 mL barrel). If your dose is 37.5 units and your syringe only has whole-unit markings, rounding to 38 units is acceptable, but request a finer-marked syringe for your next refill.

Can I split my weekly tirzepatide dose into two injections? Tirzepatide is designed for once-weekly dosing. Splitting into smaller, more frequent doses alters the pharmacokinetic profile and has not been studied. Discuss with your provider before modifying the schedule.

What happens if I inject too much tirzepatide? Over-dosing increases the risk of nausea, vomiting, diarrhea, and abdominal pain. If you inject significantly more than prescribed (e.g., 50 units instead of 25 units), contact your provider. Monitor for severe GI symptoms and dehydration.

How do I convert my dose if my pharmacy changes concentration? Use the formula: (Dose in mg ÷ New concentration in mg/mL) × 100 = Units to draw. Alternatively, reference the chart in section 2 of this article.

Do I need to refrigerate tirzepatide? Yes. Store unopened and opened vials at 36 to 46°F (2 to 8°C). Tirzepatide can be kept at room temperature (up to 86°F) for up to 21 days if needed for travel.

Why does my tirzepatide vial have a pink or orange color? Some compounding pharmacies add cyanocobalamin (vitamin B12), which is pink-orange. Check the vial label for "B12" or "cyanocobalamin." If the label doesn't mention it and the vial is colored, contact the pharmacy.

Can I use a U-500 insulin syringe for tirzepatide? No. U-500 syringes are marked differently (each unit marking represents 5 units of U-500 insulin). Using a U-500 syringe would deliver five times the intended tirzepatide dose. Only use U-100 syringes.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Clinical Pharmacokinetics. 2022.
3. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2023.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
6. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
7. Institute for Safe Medication Practices. Guidelines for subcutaneous injection volumes and site selection. 2023.
8. American Board of Obesity Medicine. Clinical guidelines for weight management with GLP-1 receptor agonists. 2024.
9. Outsourcing Facilities Association. Survey of compounding pharmacy tirzepatide concentration practices. 2025.
10. U.S. Pharmacopeia. Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. 2024.
11. FDA. Mounjaro (tirzepatide) prescribing information. May 2022.
12. FDA. Zepbound (tirzepatide) prescribing information. November 2023.
13. FDA Adverse Event Reporting System (FAERS). Tirzepatide dosing error reports, Q1 2024 - Q4 2025.
14. Patel R et al. Dosing errors in self-administered compounded GLP-1 receptor agonists: a 90-day prospective cohort study. Annals of Pharmacotherapy. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.